Skip to main content
Clinical Trials/NCT04640844
NCT04640844
Unknown
Not Applicable

Contribution of the Pharmacological Profile of the A2A Receptor to Adenosine in the Diagnosis of Myocardial Ischemia

Assistance Publique Hopitaux De Marseille1 site in 1 country170 target enrollmentJanuary 25, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Coronary Artery Disease
Sponsor
Assistance Publique Hopitaux De Marseille
Enrollment
170
Locations
1
Primary Endpoint
Dosage of adenosine
Last Updated
4 years ago

Overview

Brief Summary

The chronic coronary artery disease could be detected by a drop in the expression of A2A receptors to adenosine, while high values of the KD / EC50 ratio are a sign of coronary ischemia. Knowing the number of A2A receptors in circulating lymphocytes could allow detection of coronary artery disease and evaluating the functionality of A2A receptors in circulating lymphocytes could allow quantification of myocardial ischemia.

Thus, a simple and unique blood sample would quickly detect patients with life-threatening coronary ischemia. This would avoid prolonged hospitalizations and costly non-invasive tests (stress echocardiography, myocardial scintigraphy) in patients without coronary artery disease.

Detailed Description

The main objective of this study is to evaluate the discriminating capacities of A2A adenosine receptors expression on the surface of circulating lymphocytes for the detection of coronary artery disease in patients hospitalized for surgery of the aorta and / or arteries of the lower limbs. The secondary objectives are: Assessment of the discriminating capacities of the functionality (KD / EC50) of A2A adenosine receptors on the surface of circulating lymphocytes, for the diagnosis of myocardial ischemia in patients hospitalized for surgery of the aorta and / or arteries of legs. Determinate the best threshold for discriminating patients with coronary artery disease and estimate the discriminating performance associated with this threshold. Determinate the best threshold for discriminating patients with myocardial ischemia and estimate the discriminating performance associated with this threshold.

Registry
clinicaltrials.gov
Start Date
January 25, 2021
End Date
June 2023
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients admitted for preoperative assessment of vascular surgery of the aorta and / or arteries of the lower limbs.
  • Adult person (age\> 18).
  • Affiliated with a social security scheme.
  • Signature of informed consent.

Exclusion Criteria

  • Patients with a history of coronary artery disease awaiting revascularization.
  • Hyperthyroidism, anemia (Hb \<13 g / dL).
  • Contraindication to the practice of coronary angiography, stress echocardiography or myocardial scintigraphy.
  • Unstable hemodynamic state or cardiogenic shock.
  • Adults protected under guardianship, curatorship or legal protection.
  • Pregnant or lactating women

Outcomes

Primary Outcomes

Dosage of adenosine

Time Frame: 24 MONTHS

measuring the expression and function of lymphocyte A2A receptors.

Study Sites (1)

Loading locations...

Similar Trials